Market closed
Biomea Fusion/$BMEA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biomea Fusion
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Ticker
$BMEA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
106
Website
Biomea Fusion Metrics
BasicAdvanced
$82M
-
-$3.83
-0.28
-
Price and volume
Market cap
$82M
Beta
-0.28
52-week high
$13.43
52-week low
$1.53
Average daily volume
761K
Financial strength
Current ratio
3.153
Quick ratio
2.689
Long term debt to equity
12.976
Total debt to equity
17.007
Management effectiveness
Return on assets (TTM)
-64.35%
Return on equity (TTM)
-125.38%
Valuation
Price to book
1.53
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-0.655
Growth
Earnings per share change (TTM)
11.52%
3-year earnings per share growth (CAGR)
30.07%
What the Analysts think about Biomea Fusion
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Biomea Fusion stock.
Biomea Fusion Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Biomea Fusion Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Biomea Fusion News
AllArticlesVideos
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
GlobeNewsWire·1 month ago
Biomea Fusion Announces Leadership Transition
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Biomea Fusion stock?
Biomea Fusion (BMEA) has a market cap of $82M as of May 05, 2025.
What is the P/E ratio for Biomea Fusion stock?
The price to earnings (P/E) ratio for Biomea Fusion (BMEA) stock is 0 as of May 05, 2025.
Does Biomea Fusion stock pay dividends?
No, Biomea Fusion (BMEA) stock does not pay dividends to its shareholders as of May 05, 2025.
When is the next Biomea Fusion dividend payment date?
Biomea Fusion (BMEA) stock does not pay dividends to its shareholders.
What is the beta indicator for Biomea Fusion?
Biomea Fusion (BMEA) has a beta rating of -0.28. This means that it has an inverse relation to market volatility.